Effective June 14, 2010 Torisel will be funded in Ontario under the Ministry of Health and Long Term Care / Cancer Care Ontario's new Drug Funding Program as a first-line treatment for mrcc patients with poor prognosis (including non-clear cell histology).

CCO Funding Criteria - Temsirolimus (eff. June 14, 10)

The update is based on decisions by the Executive Officer, taking into consideration the recommendations made by the Ministry’s expert advisory committee, the Committee to Evaluate Drugs (CED).

If you have questions regarding Torisel please talk to your physician.